Merck Stands On EDGE: Arcoxia Data Presented On Eve Of FDA Action Date
Executive Summary
An increased incidence of hypertension observed in the 12-month Arcoxia EDGE trial could pose an obstacle to approval of Merck's Vioxx follow-on product as FDA's action deadline draws near
You may also be interested in...
COX-2 Safety Will Be Discussed By FDA Advisory Committee In Early 2005
FDA will hold an advisory committee in early 2005 to discuss the cardiovascular safety profile of COX-2 inhibitors, Acting Deputy Commissioner of Operations Janet Woodcock, MD, said at an American College of Rheumatology meeting Oct. 18 in San Antonio
COX-2 Safety Will Be Discussed By FDA Advisory Committee In Early 2005
FDA will hold an advisory committee in early 2005 to discuss the cardiovascular safety profile of COX-2 inhibitors, Acting Deputy Commissioner of Operations Janet Woodcock, MD, said at an American College of Rheumatology meeting Oct. 18 in San Antonio
Merck’s “VIGORous” Defense Of Vioxx; Novartis, Wyeth Studies Might Help
Merck still believes that the initial cardiovascular safety signal seen for Vioxx can be explained by a cardioprotective effect from naproxen, the company said during an Oct. 13 press conference in New York City